DaVita Inc. (DVA) Stock: Price, Forecast & Analyst Target
DaVita Inc. (DVA) — MoonshotScore 76/100 (Strong band), calculated Nov 18, 2026. Price $156.24 (-3.43%), as of the Nov 19, 2026 trading session; market cap $9.83B. Expected results Feb 1, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 17.36× (cash as of Sep 30, 2026) · expected results Feb 1, 2027
DaVita Inc. · DVA · NYSE · Healthcare · Medical - Care Facilities
Research dated 2026-09-13: DaVita delivers recurring dialysis treatments and related renal care through outpatient centers, hospitals and patients’ homes, with laboratory and integrated-care services extending the relationship beyond the dialysis chair. Its earnings path rests on treatment activity and revenue per treatment supporting cash generation while a heavy debt load limits financial flexibility.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · DaVita (DVA)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite growth, at a cheap price, though quality and the balance sheet are only decent; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $3.42B (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- expected results Feb 1, 2027
Helping: an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 77 | Strong | |
| 77 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $156.24 | |
| Change on the day | -3.43% | |
| 52-week range | $101.00–$247.49 | |
| Market capitalisation | $9.83B | — |
| Price / earnings (trailing) | 13.28 | |
| Shares traded on the day | 988.6K | |
| Beta (volatility vs the S&P 500) | 0.86 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We now expect IKC to deliver at least $65 million of adjusted operating income in 2026, an increase of at least $25 million over the prior guidance.
Javier Rodriguez · Statement from
We now expect this year's IKC adjusted operating income to be at least $65 million, representing a $45 million improvement over last year and a $25 million improvement over our prior guidance.
Joel Ackerman · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for DaVita (DVA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is DaVita (DVA), and what does it report?
Short answer · as of
DaVita is primarily a kidney-care operator, not a general medical-facilities business. It treats chronic kidney failure through outpatient dialysis centers, provides acute dialysis in hospitals and home-based care, runs diagnostic laboratories, and supports other dialysis facilities and physicians.
Research dated 2026-09-13.
Reported revenue is concentrated in domestic dialysis and related laboratory services. The broader portfolio includes integrated kidney care, vascular-access interventions, clinical research and international clinics, but dialysis treatment activity remains the core economic unit.
What do the latest results show for DaVita (DVA)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $3.42B.
Research dated 2026-09-13.
The latest completed year paired revenue growth with lower net income. More recent results improved sharply from the preceding period: revenue recovered, while gross profit, operating income, net income and diluted earnings per share all advanced. Revenue and earnings per share also cleared consensus again.
Treatment activity and revenue earned per treatment form the operating bridge. Management expects treatment growth near the upper end of its prior range, yet expects full-period revenue-per-treatment growth to moderate from the pace recorded earlier in the year. Management also expects international operations and Integrated Kidney Care to contribute to operating-income growth.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $3.58B Sep 30, 2026
- Latest quarter · SG&A
- $408.70M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $499.25M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $3.58B | Not available | $408.70M | $499.25M |
| Jun 30, 2026 | $3.55B | Not available | $423.46M | $570.82M |
| Mar 31, 2026 | $3.42B | Not available | $421.91M | $481.89M |
| Dec 31, 2025 | $3.62B | Not available | $472.36M | $551.21M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.58B Oct 29, 2026
- Latest report · revenue estimate
- $3.52B Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $3.58B | $3.52B | $3.8200 | $3.5700 |
| Aug 4, 2026 | $3.55B | $3.50B | $4.0200 | $3.8800 |
| May 5, 2026 | $3.42B | $3.36B | $2.8700 | $2.4100 |
| Feb 2, 2026 | $3.62B | $3.51B | $3.4000 | $3.2400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $3.42B | $150M | $2.04 (diluted) |
| Q4 FY2025 | $3.62B | $234M | $2.45 (diluted) |
| Q1 FY2026 | $3.42B | $198M | $2.87 (diluted) |
| Q2 FY2026 | $3.55B | $265M | $4.02 (diluted) |
What are the financial strengths and risks for DaVita (DVA)?
Short answer
Cash and short-term investments were $566.30M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $518.83M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operations generated positive cash flow throughout the reported series, and cash generation remained positive after capital spending. That gives DaVita an internally funded base for maintaining its treatment network.
Debt substantially exceeds cash and investments, while cash and short-term investments have declined across the reported window. Near-term liquidity ratios indicate coverage of near-term obligations, but the negative debt-to-equity reading makes conventional leverage comparisons less informative. Stalling treatment growth alongside moderating revenue per treatment would weaken the cash available to manage that leverage.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.68 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $518.83M Sep 30, 2026
- Previous quarter · operating cash flow
- $490.07M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $518.83M | −$159.49M |
| Jun 30, 2026 | $490.07M | −$169.82M |
| Mar 31, 2026 | $320.83M | −$102.02M |
| Dec 31, 2025 | $540.73M | −$145.43M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at DaVita (DVA)?
Short answer · as of
The next earnings report is expected on Feb 1, 2027.
Research dated 2026-09-13.
At the scheduled earnings release, compare treatment activity with management’s improved volume trajectory and test whether revenue per treatment is moderating toward the full-period outlook. Consensus also implies sequential moderation in revenue and earnings per share, making the direction of operating profit particularly informative.
Integrated Kidney Care deserves separate attention. Management expects timing in that business to drive a sizable step-up in adjusted operating income between the coming reporting periods, while international operations and Integrated Kidney Care are each expected to add to full-period profit growth.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We still anticipate full year free cash flow between $1 billion and $1.25 billion.
Joel Ackerman ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does DaVita compare with its peers?
Short answer
DaVita's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
DaVita differs from diversified care-facility operators because demand centers on repeated, medically necessary dialysis treatments rather than broad hospital or clinic utilization. The same kidney-care relationship can span an outpatient center, a hospital, the patient’s home and related laboratory work.
Integrated Kidney Care adds chronic-disease management and risk-based care arrangements to the treatment network. That broadens DaVita’s exposure beyond reimbursement for dialysis sessions, although reported revenue remains concentrated in domestic dialysis and related laboratory services.
| Company | Price | Market value | Score |
|---|---|---|---|
| $271.34 Nov 18, 2026 | $21.6B | 94 5-pillar Nov 18, 2026 | |
| $13.77 Nov 18, 2026 | $5.24B | 92 5-pillar Nov 18, 2026 | |
| $186.07 Nov 18, 2026 | $10.7B | 91 5-pillar Nov 18, 2026 | |
| $546.72 Nov 18, 2026 | $7.09B | 85 5-pillar Nov 18, 2026 | |
| $31.71 Nov 18, 2026 | $4.75B | 85 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $132.25 Nov 19, 2026 | $13.0B | 81 5-pillar Nov 18, 2026 | |
| $20.95 Nov 18, 2026 | $10.9B | 80 5-pillar Nov 18, 2026 | |
| DaVita (DVA) — this page | $156.24 | $9.83B | 76 |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $86.48 Nov 18, 2026 | $14.7B | 66 5-pillar Nov 18, 2026 | |
| $61.43 Nov 18, 2026 | $11.9B | 58 5-pillar Nov 18, 2026 | |
| $16.26 Nov 19, 2026 | $4.57B | 38 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $215.00 – $287.00
- Consensus target
- $238.50
- Median target
- $222.00
Consensus record · Captured .
Measured against a quoted price of $156.24 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 15, 2026
- Transactions
- 26
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 6
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 92.9% Period end Sep 30, 2026
- Previous quarter · ownership
- 91.7% Prior to period end Sep 30, 2026
- Reporting holders
- 659 Period end Sep 30, 2026
- Previous quarter · holders
- 668 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Berkshire Hathaway INC | 28,697,229 |
| Blackrock, INC. | 2,733,890 |
| Vanguard Capital Management LLC | 2,259,222 |
| Morgan Stanley | 1,641,878 |
| Vanguard Portfolio Management LLC | 1,573,788 |
Tracked investors
Which of the 16 named investors we follow held DVA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Berkshire Hathaway | Warren Buffett, Greg Abel | Q3 2026 | 1.65% | $5.02B | Trimmed −0.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about DaVita (DVA)?
What Investors Ask About DaVita (DVA) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does DaVita earn revenue from outpatient dialysis?
DaVita earns revenue by delivering recurring dialysis treatments and related laboratory services. Treatment activity and revenue received per treatment are therefore the key operating levers.
Why does DaVita track revenue per treatment?
Revenue per treatment shows how reimbursement and service mix translate each dialysis session into revenue. Management expects its growth to moderate from the pace recorded earlier in the year, even as treatment activity trends toward the stronger end of prior expectations.
What does DaVita Integrated Kidney Care add to dialysis?
Integrated Kidney Care extends DaVita into chronic-disease management and risk-based care arrangements. Management expects the business to contribute to profit growth, with timing shaping the progression of operating income.
Is Berkshire Hathaway a major DaVita shareholder?
Berkshire Hathaway is the largest named institutional holder. Institutional investors collectively own most of the company, although their aggregate ownership edged lower in the latest disclosed period.
What is the DVA stock price today?
The last price recorded for DaVita Inc. (DVA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DVA price target?
The analyst consensus price target for DaVita Inc. (DVA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 77 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold DVA
Funds in our ETF coverage that list DVA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| The Obesity ETF (SLIM) | 4.55% | |
| XHS ETF | 2.60% | |
| QSY ETF | 1.67% | |
| DWSH ETF | 1.36% | |
| AdvisorShares Insider Advantage ETF (SURE) | 1.31% |